Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-08-06 Capital/Financing Update
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the resale of common stock by a selling stockholder. It includes extensive information about the offering, the company, risk factors, use of proceeds, dividend policy, selling stockholder, plan of distribution, and legal matters. The document is clearly a registration and offering prospectus for securities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. This type of filing corresponds to a Capital/Financing Update as it relates to fundraising and capital structure changes through a stock offering.
2024-08-06 English
Regulatory Filings 2024
Regulatory Filings
2024-08-05 English
Regulatory Filings 2024
Regulatory Filings
2024-08-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter from Chromocell Therapeutics Corporation to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal communication related to a regulatory filing process, specifically concerning the registration statement effectiveness. The document is short (1628 characters) and does not contain financial data or report content itself. It is not the registration statement or a financial report but an announcement/request related to the filing process. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-08-02 English
Regulatory Filings 2024
Regulatory Filings
2024-08-02 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated July 29, 2024, for Chromocell Therapeutics Corporation. It is a registration statement under the Securities Act of 1933, used for initial public offerings or other securities offerings. The text includes detailed information about the offering, selling stockholder, use of proceeds, risk factors, and other disclosures typical of a registration statement prospectus. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to the company's securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or certification, supporting a high confidence level.
2024-07-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.